rs673548 — APOB

Intronic APOB variant associated with modest differences in apolipoprotein B levels, cardiovascular risk, and ischemic stroke susceptibility across populations.

Moderate Risk Factor Share

Details

Gene: APOB
Chromosome: 2
Risk allele: G
Clinical: Risk Factor
Evidence: Moderate

Population Frequency

37%

57%

External

SNPedia ClinVar dbSNP

See your personal result for APOB

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

APOB rs673548 — Intronic Variant Linked to Cardiovascular and Lipid Risk

Apolipoprotein B (APOB) is the primary protein component of low-density lipoprotein (LDL) particles. Every LDL particle contains exactly one APOB-100 molecule, which acts as the structural backbone and also serves as the ligand that allows LDL to bind LDL receptors on liver and other cells. Higher plasma APOB concentrations — even when LDL-C appears normal — are a direct measure of atherogenic particle burden ¹¹ Glavinovic et al. Physiological Bases for the Superiority of Apolipoprotein B Over LDL Cholesterol as a Marker of Cardiovascular Risk. J Am Heart Assoc, 2022.

rs673548 is an intronic variant located 79 nucleotides upstream of exon 3697 in NM_000384.3 (c.3697-79C>T in transcript notation; G>A on the plus strand at chr2:21014672). It does not change the APOB amino acid sequence. Instead, intronic variants at this position may influence mRNA splicing efficiency, pre-mRNA processing, or serve as a tag for nearby regulatory variants affecting APOB expression levels.

The Mechanism

As an intron variant, rs673548 itself does not alter the APOB-100 protein. Its functional significance likely derives from linkage disequilibrium²² linkage disequilibrium
LD is the tendency for nearby alleles to be inherited together; a marker SNP can tag an unobserved causal variant with functional variants elsewhere in the APOB locus, or from direct effects on intronic splicing regulatory elements. The APOB locus harbors multiple variants in strong LD — rs673548, rs676210 (missense, Pro2739Leu), rs1042034 (missense, Ser4338Ile), and rs693 — that are often inherited together as a haplotype block. The cardiovascular associations attributed to rs673548 may partly reflect the combined effect of this haplotype rather than rs673548 acting alone.

The Evidence

A 2022 case-control study³³ 2022 case-control study
Aceves-Ramírez et al. Analysis of the APOB gene and apolipoprotein B serum levels in a Mexican population with acute coronary syndrome. Genetics Research, 2022 enrolled 300 acute coronary syndrome (ACS) patients and 300 matched controls in a Mexican population. rs673548 showed a statistically significant allelic difference between groups (OR=1.33, p=0.030). The study also identified a risk haplotype (TAGT, encompassing rs1469513, rs673548, rs676210, and rs1042034) with OR=2.14 (95% CI 1.50–3.04, p<0.001). Notably, APOB serum levels did not differ significantly by genotype in either group, suggesting the variant tags a structural haplotype rather than directly altering circulating apoB protein concentration.

A 2017 case-control study in Chinese Han males⁴⁴ 2017 case-control study in Chinese Han males
Zhou et al. Variants in the APOB gene associated with ischemic stroke susceptibility in Chinese Han male population. Oncotarget, 2017 (325 ischemic stroke patients, 399 healthy controls) found the G allele of rs673548 significantly associated with increased ischemic stroke risk (OR=1.28, 95% CI 1.02–1.62, p=0.034). In the same population, the log-additive model gave an OR of 1.27 per G allele copy. This study was restricted to males and a single Chinese Han cohort, which limits generalizability.

A complementary haplotype analysis⁵⁵ haplotype analysis
Xiao et al. Association analysis of APO gene polymorphisms with ischemic stroke risk: a case-control study in Chinese Han population. Oncotarget, 2017 (488 cases, 503 controls) identified strong linkage involving rs673548 with rs1042034, rs676210, and rs693 in a block associated with stroke risk, consistent with the haplotype model.

Practical Actions

The G allele is the reference allele and is most common in Europeans (~79%) and Africans (~79%), but notably less frequent in East Asians (~27%). The A allele — minor in most populations but major in East Asians (~73%) — appears modestly protective in the available studies. Effect sizes are modest (OR ~1.28–1.33 for G), and current evidence comes from relatively small, population-specific case-control studies. This variant should be interpreted in the context of the full APOB haplotype and overall cardiovascular risk profile.

For GG carriers, the most evidence-supported strategies are monitoring serum ApoB directly (rather than relying solely on LDL-C), and ensuring LDL-C targets are met with clinical guidance. Statin therapy lowers APOB-containing lipoprotein particles regardless of rs673548 genotype, so this SNP does not alter statin eligibility — but GG carriers with borderline cardiovascular risk may benefit from earlier lipid panel monitoring that includes direct ApoB measurement.

Interactions

rs673548 sits in a haplotype block with rs676210 (p.Pro2739Leu), rs1042034 (p.Ser4338Ile), and rs693 — these variants are often co-inherited. The combined TAGT haplotype carried substantially higher ACS risk (OR=2.14) than rs673548 alone (OR=1.33), suggesting the variant's risk signal amplifies in the context of this linked block. Carriers of multiple LDL-raising variants across the TRIB1, GCKR, and APOB loci face cumulative atherogenic risk; a lipid panel that includes direct ApoB quantification (target <80 mg/dL for high cardiovascular risk) is more informative than LDL-C alone in this setting.

Genotype Interpretations

What each possible genotype means for this variant:

GG “Reference Genotype” Normal

Common APOB reference genotype — modest cardiovascular risk signal

You carry two copies of the G allele at rs673548, the most common genotype in European (62%) and African (~62%) populations. The G allele is the GRCh38 reference allele. Studies have linked the G allele to modestly higher risk of acute coronary syndrome and ischemic stroke (OR approximately 1.28–1.33 per allele in small case-control studies), though these associations are from population-specific cohorts and the absolute effect is modest. Standard lipid monitoring applies; no targeted intervention is required solely based on this genotype.

AA “Two Protective A Alleles” Beneficial

Two copies of the A allele — lower risk associated with this variant

You carry two copies of the A allele at rs673548. The A allele appears modestly protective against the cardiovascular associations linked to the G allele in case-control studies. This genotype is relatively rare in Europeans (~4%) but much more common in East Asian populations (~53%). The evidence for meaningful cardiovascular protection from the AA genotype specifically is limited — available studies report allele-level effects rather than AA-specific odds ratios.

In East Asian populations where A is the major allele, the stroke and ACS associations of rs673548 are less established, as the primary studies were conducted in cohorts where G was the risk-enriched allele.

AG “One Protective A Allele” Intermediate Caution

One copy of the A allele — modestly intermediate risk profile

You carry one G allele and one A allele at rs673548. The A allele is the alternate allele that appears modestly protective based on current evidence — studies linking the G allele to cardiovascular risk suggest that A-allele carriers occupy an intermediate position. This is the most common genotype globally (approximately 37% of the population), and about 33% of Europeans share it.

The evidence for this variant is moderate: derived from small, population-specific case-control studies. Your risk profile here is meaningfully influenced by other cardiovascular risk factors (lipid levels, blood pressure, diabetes, smoking) more than by this genotype alone.